Acthar Proposed Giveaway Program Raises Kickback Concerns, OIG Says
Executive Summary
High price of Mallinckrodt’s H.P. Acthar Gel is important factor in conclusion, HHS Office of Inspector General advisory opinion notes.
You may also be interested in...
Mallinckrodt Settles Portion Of DOJ's Acthar Gel Kickback Claims; Charity Copay Probe Continues
$15.4m fine will resolve claims of "wining and dining" doctors to get them to prescribe Acthar. Mallinckrodt dropped NORD and switched to Chronic Disease Fund to administer its copay assistance program, a move that Mallinckrodt’s COO purportedly described as "mom & pop vs. WalMart."
Free Imbruvica Program Cleared By HHS Inspector General
An advisory opinion says a program sponsored by Johnson & Johnson and AbbVie to provide up to 60 days of the cancer drug Imbruvica for free to patients who experience delays in receiving insurance coverage approval is at low risk of raising anti-kickback concerns.
US Medicare Price Negotiation: Gaming FDA Approval Dates Could Delay Drug Selection
The early February date for publishing the list of products eligible for price negotiations could dictate approval strategies for drugs with potential for big sales in Medicare going forward.